Nevanac and Dexamethasone drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Nevanac (nepafenac) and Dexamethasone (dexamethasone). Common drug interactions include blindness unilateral among females and haemolytic uraemic syndrome among males.

The phase IV clinical study analyzes what interactions people have when they take Nevanac and Dexamethasone. It is created by eHealthMe based on reports of 58 people who take the same drugs from the FDA, and is updated regularly.

What is Nevanac?

Nevanac has active ingredients of nepafenac. It is often used in cataract removal. eHealthMe is studying from 1,755 Nevanac users. Check the latest studies of Nevanac.

What is Dexamethasone?

Dexamethasone has active ingredients of dexamethasone. It is often used in multiple myeloma. eHealthMe is studying from 161,927 Dexamethasone users. Check the latest studies of Dexamethasone.



On Jul, 14, 2026

58 people who take Nevanac and Dexamethasone together, and have interactions are studied.

Nevanac and Dexamethasone drug interactions.

What are the common drug interactions of Nevanac and Dexamethasone, by gender? *:

female:

  1. Blindness unilateral
  2. Dizziness
  3. Eye inflammation
  4. Eye pain
  5. Fatigue (feeling of tiredness)
  6. Fibroadenoma of breast (breast lump)
  7. Headache (pain in head)
  8. Hemiparesis (weakness on one side of the body)
  9. Macular oedema (fluid and protein deposits collect on or under the macula of the eye (a yellow central area of the retina) and causes it to thicken)
  10. Ocular hypertension (intraocular pressure higher than normal)

male:

  1. Haemolytic uraemic syndrome (blood clotting disease caused by e. coli infection, birth control pills, pneumonia, medications, and more)
  2. Pulmonary embolism (blockage of the main artery of the lung)
  3. Ocular vasculitis (inflammation eye blood vessels)
  4. Retinal vasculitis (a sight-threatening inflammatory eye condition that involves the retinal vessels)
  5. Uveitis (inflammation of the uvea)
  6. Vision blurred
  7. Vitreous opacities (vitreous opacities generally develop as aging changes within the eye)
  8. Embolic pneumonia (infarction following embolization of a pulmonary/lung artery or arteries)
  9. Toxic anterior segment syndrome
  10. Corneal striae (presence of an excessive amount of fluid in or around cells)

What are the common drug interactions of Nevanac and Dexamethasone, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

  1. Hypotony of eye (low intraocular pressure (iop))

20-29:

n/a

30-39:

  1. Blindness unilateral
  2. Dizziness
  3. Eye inflammation
  4. Eye pain
  5. Fatigue (feeling of tiredness)
  6. Fibroadenoma of breast (breast lump)
  7. Headache (pain in head)
  8. Hemiparesis (weakness on one side of the body)
  9. Macular oedema (fluid and protein deposits collect on or under the macula of the eye (a yellow central area of the retina) and causes it to thicken)
  10. Ocular hypertension (intraocular pressure higher than normal)

40-49:

  1. Alanine aminotransferase increased
  2. Aspartate aminotransferase increased
  3. Blood chloride increased
  4. Blood creatinine increased
  5. Blood glucose increased
  6. Blood magnesium increased
  7. Blood sodium increased
  8. Blood urea increased
  9. Bronchopneumonia (inflammation of the lungs, arising in the bronchi or bronchioles)
  10. Confusional state

50-59:

  1. Embolism (obstruction of an artery, typically by a clot of blood or an air bubble)
  2. Toxic anterior segment syndrome
  3. Bacterial infection
  4. Haemolytic uraemic syndrome (blood clotting disease caused by e. coli infection, birth control pills, pneumonia, medications, and more)
  5. Pulmonary embolism (blockage of the main artery of the lung)
  6. Infection
  7. Pneumonia
  8. Embolic pneumonia (infarction following embolization of a pulmonary/lung artery or arteries)

60+:

  1. Toxic anterior segment syndrome
  2. Cough
  3. Dyspnoea (difficult or laboured respiration)
  4. Pulmonary haemorrhage (acute bleeding from the lung)
  5. Tongue discolouration (colour change of tongue)

What are the existing conditions these people have? *

  1. C-Reactive Protein Increased: 16 people, 27.59%
  2. Uveitis (inflammation of the uvea): 3 people, 5.17%

* Approximation only. Some reports may have incomplete information.

Do you take Nevanac and Dexamethasone?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Nevanac and Dexamethasone:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Nevanac:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Dexamethasone:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Nevanac and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Dexamethasone and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Related publications that referenced our studies


How the study uses the data?

The study uses data from the FDA. It is based on nepafenac and dexamethasone (the active ingredients of Nevanac and Dexamethasone, respectively), and Nevanac and Dexamethasone (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: